R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
Market Access Neurotech patents in Europe: Methods, medical devices, and t... The field of neurotechnology is rapidly evolving, bringing together advances in neuroscience, engineering, materials science, and computing.
Market Access Early strategic evidence planning is a key success factor in... As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.